About Ataraxis
Ataraxis is a clinical AI company pioneering precision medicine through advanced artificial intelligence methods applied to multi-modal medical data. The company's mission is to completely personalize cancer treatment by predicting patient outcomes and treatment response at the individual level. Ataraxis develops AI foundation models, including their proprietary Falcon model trained on hundreds of millions of pan-cancer pathology slide images, that extract novel clinical, morphological, and molecular features beyond what single data types can reveal. Their flagship platform, Ataraxis Breast, offers clinically validated prognostic and predictive tools for breast cancer, including recurrence risk assessment, chemotherapy benefit prediction, and neoadjuvant therapy response prediction. Unlike traditional molecular genomic tests, Ataraxis delivers results within 24 hours without exhausting physical tissue samples. The company's proprietary Ataraxis Tau framework uses causal inference methods to estimate individualized treatment effects from real-world data, moving beyond population-level predictions to provide personalized treatment benefit assessments. Ataraxis actively collaborates with top international cancer centers and health systems on development, validation, and clinical implementation of their technology, with peer-reviewed publications in Nature Communications and presentations at major oncology conferences including ASCO, SABCS, and ESMO.
Mission & Story
Mission
Our goal is to completely personalize treatment by predicting patient outcomes and treatment response, developing novel AI methods applied to multi-modal data.
Clinical Focus
Medical conditions and clinical areas addressed by Ataraxis.
Who It Serves
Milestones & Awards
Recent Milestones
Series A funding of $20.4 million announced; Launch of Ataraxis Breast NEO (April 2026) for predicting response to neoadjuvant therapy; Multiple ASCO 2026 presentations; Nature Communications publication (May 2026); Analytical validation study published in Diagnostics (March 2026)
Key Partnerships
Social & Media
Latest Updates
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Beacon Biosignals
Beacon Biosignals is a precision neuroscience platform that uses AI-powered technology to accelerate drug development and power home sleep testing diagnostics. The company collects, integrates, and analyzes EEG data across the full drug development lifecycle.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.